35results about "Genetic material ingredients" patented technology

The present invention provides a monoclonal anti-idiotype antibody 11D10 that elicits an immune response against a specific epitope of a high molecular weight mucin of human milk fat globule (HMFG) and a hybridoma that produces 11D10. The hybridoma that produces 11D10 was selected by specific procedures. 11D10 induces an immunological response to HMFG in nice, rabbits, monkeys and patients with advanced HMFG-associated tumors. This invention provides compositions derived from polynucleotide sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 11D10, as well as polypeptides encoded thereby. The invention also provides compositions which can be used in the detection or treatment of HMFG-associated tumors.

The present invention relates to oligo double-stranded RNAs for use in knockdown of the expression of Bcl-2 protein known as a suppressor for apoptosis, and pharmaceutical compositions containing them. It is known that Bcl-2 protein is over-expressed in diseases such as cancer, and by this over-expression, the growth of cancer cells is continued and the drug resistance to anti-cancer agents is caused. The present invention provides highly active oligo double-stranded RNAs cleaving bcl-2 mRNA and further provides pharmaceutical compositions comprising a complex of the oligo double-stranded RNA and a suitable carrier for inhibiting the expression of Bcl-2 protein.

The present invention calls utilized genes differentially expressed in target cells to design vaccines to generate an immune response. Unlike prior art methods that seek to identify antigenic proteins from phenotypic analysis, the subject method applies functional genomics for antigen identification. The method is exemplified herein and therefore provides compositions and methods for inducing an immune response against gp 100 melanoma cells and for inducing an immune response against HER-2+cells. Cancer vaccines and adoptive immunotherapeutic methods to treat and prevent conditions associated with the presence of these cells in a subject also are provided. The methods can be practiced by administering the appropriate gene or cancer vaccine, antibody, protein, polypeptide, antigen-presenting cell or immune effector cell.

The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.

This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the SEM A4D gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the SEMA4D gene.

The invention discloses a human beta globin gene containing a human beta globin gene promoter, a recombinant adeno-associated virus vector containing the human beta globin gene, and a method for preparing the recombinant vector. The recombinant adeno-associated virus vector inserts an HS2 segment, an HS3 segment and an HS4 segment of a human beta globin gene cluster enhancer core sequence and a human beta globin gene sequence containing the human beta globin gene promoter into repeated sequence ITRs on the reverse terminal of an adeno-associated virus. The recombinant vector has high transfection efficiency; and mediated exogenous genes can be expressed in vivo for a long time, have good safety and can be used for gene therapy of beta Mediterranean anemia.

The invention relates to methods of treating melanoma using a herpes simplex virus in combination with an immune checkpoint inhibitor.

PCT No. PCT/JP94/00237 Sec. 371 Date Oct. 23, 1995 Sec. 102(e) Date Oct. 23, 1995 PCT Filed Feb. 17, 1994 PCT Pub. No. WO94/19314 PCT Pub. Date Sep. 1, 1994The object of the invention is to provide a lipid device functionally equivalent to the so-called cationic liposome and of lesser toxicity and a lipid or the like as a component of the device. The compound of the invention includes but is not limited to 3-O-(4-dimethylaminobutanoyl)-1,2-O-dioleylglycerol, 3-O-(2-dimethylaminoethyl)carbamoyl-1,2-O-dioleylglycerol, 3-O-(2-diethylaminoethyl) carbamoyl-1,2-O-dioleylglycerol and 2-O-(2-diethylaminoethyl) carbamoyl-1,3-O-dioleoylglycerol. The device of the invention comprises such a lipid and a phospholipid. By administering a double-stranded RNA, for instance, together with the device of the invention, the double-stranded RNA can be safely delivered to the site of action.

The presently disclosed subject matter relates generally to the fields of molecular biology and medicine. More particularly, it concerns methods involving the use of GSK3 inhibitors in combination with radiation therapies. In some embodiments, administration of a GSK3 inhibitor to a subject results in an amelioration of cognitive decline, toxicity to vascular endothelial cells, and/or neuron death associated with radiation therapy alone.

Novel MCP-1 splice variant polypeptides and polynucleotides encoding same are provided. Also provided are pharmaceutical compositions comprising the splice variant polypeptides and polynucleotides, vectors and host cells comprising same. The compositions of the present invention are useful to treat various MCP-1 related disorders as well as for diagnosing, determining predisposition and/or prognosis of various disorders.

A recombinant vector for delivering A3G genes into human cells comprising (i) a gene expression block including an A3G gene selected from a wild type A3G gene represented by SEQ ID NO: 1 and a mutant A3G gene and (ii) a group of elements from a modified lentiviral vector including lentiviral regions of packaging signal (ψ, psi), LTRs, RRE, and PBS; wherein said A3G gene is operably linked to the packaging signal (ψ, psi), LTRs, RRE, and PBS.

The invention relates to the technical field of biomedicine, in particular to a liver bud stem cell, a preparation method and the use thereof. The stem cell biology obtains the rapid development in the recent years. The isolation, the culture and the in-depth research of liver stem/progenitor cells have very important values for the occurrence mechanism of liver development, liver tumor and liver regeneration and the prevention and the treatment of various liver diseases. The currently and successfully cultured liver stem/progenitor cell systems are very limited. The invention is the multipotential stem cell which is isolated from a human embryonic liver bud tissue with the pregnancy of 4.5 to 6 weeks, thereby having significance for knowing the liver development, the regeneration and other related medical problems, providing an ideal cell model for the research of the liver stem cell biology and possibly providing an ideal cell source for the research of the cell therapy of liver diseases caused by various factors, the drug screening, the tissue engineering and other fields.

The invention belongs to the field of biological medicine, and relates to a long-acting HIV fusion inhibitor for treating acquired immune deficiency syndrome and application thereof. The long-acting HIV fusion inhibitor comprises a polypeptide part for inhibiting HIV membrane fusion and a part capable of being specifically combined with human immune globulin Fc, it is proved through experiments that the half-life period of the long-acting HIV fusion inhibitor in a rhesus monkey is about 11 times that of the HIV fusion inhibitor T20 which is first approved for marketing and has excellent antiviral activity to HIV-1IIIB and HIV-1Bal, the IC50 values are about 5.9 nM and 2.57 nM respectively, the antiviral activity is about 3 times that of T20, and the long-acting HIV fusion inhibitor has low toxicity to cells. The long-acting HIV fusion inhibitor IBP-CP24 polypeptide can be used for preparing a drug for resisting human immunodeficiency viruses for a long time and providing a new strategy for prolonging the half-life period of protein and polypeptide drugs in the body.

The invention discloses application of PCSK9 in diagnosis and treatment of esophageal squamous carcinoma. The esophageal squamous carcinoma is a common digestive tract malignant tumor, experiments prove that PCSK9 gene expression in the esophageal squamous carcinoma tissues is up-regulated, PCSK9 gene overexpression can promote the growth of esophageal squamous cancer cells, and the excessive proliferation of the esophageal squamous cancer cells can be inhibited by inhibiting the PCSK9 gene overexpression. The invention provides an esophageal squamous carcinoma diagnosis method and meanwhile provides a potential drug target for treating the esophageal squamous carcinomas.

The present invention provides transgenic mice deficient in corticotropin releasing factor receptor 2 (CRFR2). Mice deficient for CRFR1 exhibit decreased anxiety-like behavior and a decreased stress response. In contrast, CRFR2 null mutant mice are hypersensitive to stress and display increased anxiety-like behavior. These mice are useful for the study of anxiety, depression, and the physiology of the HPA axis. CRFR2 null mutant mice also exhibit increased angiogenesis in all tissues examined. Thus, CRFR2 antagonists may be used to stimulate angiogenesis for the treatment of various conditions. In contrast, CRFR2 agonists may be used to inhibit angiogenesis. A combination of urocortin and bFGF was observed to stimulate rapid hair growth.

Antisense compounds, compositions and methods are provided for modulating the expression of mucin 1, transmembrane. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding mucin 1, transmembrane. Methods of using these compounds for modulation of mucin 1, transmembrane expression and for treatment of diseases associated with expression of mucin 1, transmembrane are provided.

The invention relates to a protein and a pharmaceutical composition for treating ischemic diseases. Specifically, it is found by the inventor that insulin-like growth factor binding protein, especially insulin like growth factor binding protein-4 (IGFBP-4) has an excellent effect on treating ischemic diseases. IGFBP-4 protein can promote vascular proliferation and the differentiation of stem cells into myocardial cells. IGFBP-4 protein also has good therapeutic and preventive effects on ischemic diseases, especially on myocardial ischemia and lower limb ischemia and has no toxic or side-effect.

The present invention relates to a composition for transfecting a cell with a genetic material comprising a first agent capable of directing the genetic material away from the acidic compartments in the cell and a second agent capable of stabilizing the microtubule or a network thereof. The invention also relates to the use of the composition in the manufacture of a medicament for treating a disease, a method for delivering a genetic material into a cell and a kit.

The invention discloses a method for constructing a pSU6-miR-122 vector capable of being used for expressing miR-122 and application of the pSU6-miR-122 vector. The method comprises the following steps of: a, chemically synthesizing oligonucleotide chains, wherein antisense chains and sense chains are complementary; adding AGCT onto the 5' end to form a viscous protruding end; b, annealing the sense chains and the antisense chains so as to form a segment with BamHI and HindIII viscous ends; c, linking the segment to a vector pSilencer-2.1-U6, wherein the vector is doubly digested by BamHI and HindIII; d, transforming colibacillus Stb13 competent cells; and e, screening positive clones to obtain Psu6-miR-122 vector plasmids expressing the miR-122. According to the application of the vector in drugs for inhibiting hepatitis B virus, the efficiency for resisting hepatitis B virus infection is high; the specificity is strong; the vector is non-toxic to normal cells; and the inhibition ratio to hepatitis B virus replication is 85.2%.

The invention belongs to the field of biomedical materials and discloses application of miR-141 in the preparing of anti-osteoporosis and bone-resorption-inhibiting preparations. Experiments prove that the miR-141 inhibits the differentiation process of osteoclasts by regulating the expression of genes related to osteoclast differentiation. The miR-141 can inhibit bone mass loss and osteoporosis, so that the miR-141 can be used for preparing the various biomedical anti-osteoporosis and bone-resorption-inhibiting preparations.

The invention discloses a cationic macromolecular proteolipid gene medicine carrier, a preparation method and an application, wherein the cationic macromolecular proteolipid gene medicine carrier is a macromolecular transferrin liposome prepared by transferrin-long-chain alkyl quaternary ammonium salt and a lipid ingredient in a mass ratio of (0.05 to 20): 1. The result of a gene transfection experiment indicates that the gene transfection efficiency of the macromolecular transferrin liposome in 293T cells, NIH-3T3 cells, liver cancer Huh-7 cells, SMMC-7721 cells, lung cancer A549 cells is equivalent to the gene transfection efficiency of a positive control, namely a cationic liposome Lipofectamine TM2000. The system of the cationic macromolecular proteolipid gene medicine carrier is good in biocompatibility, low in cytotoxicity, and capable of being used as an excellent non-viral gene medicine delivery carrier.

A pharmaceutical composition for treating cancer, containing a crRNA and an endonuclease as active ingredients is disclosed. The composition can be customized according to the needs of patients or cell types by specifically treating cancer cells on the basis of specific binding properties of DNA and RNA. The nuclease activity of a CRISPR PLUS system, containing both an endonuclease and an exonuclease can be activated by means of the binding between crRNA and a gene specifically found in cancer cells. Therefore, the cancer treatment effect of the composition is more specific than that of other anti-cancer agents that have been developed up till now.

The invention discloses a recombinant expression carrier containing a schistosoma japonicum gene which is a schistosoma japonicum thioredoxin peroxidase II gene. The invention also discloses a preparation method of the schistosoma japonicum thioredoxin peroxidase II and the application of the recombinant expression carrier. The recombinant expression carrier containing the schistosoma japonicum gene can highly express the schistosoma japonicum thioredoxin peroxidase II, and the highly expressed recombinant schistosoma japonicum thioredoxin peroxidase II can induce mouse to generate the protection function of resisting the infection of schistosoma japonicum at a certain level.

The invention relates to an improved adenovirus, a construction method of the system of the improved adenovirus, and an application of the improved adenovirus. After a fiber gene is knocked out of anAD293 cell, not only an fiber protein is expressed on the surface of the adenovirus particles, a fusion probe of the fiber protein and a target protein is also expressed on the surface, and the falsepositive influences of only fiber protein virus particles are eliminated through only the fusion protein of the fiber protein and the target protein on the surface of the virus particles.